Oruka Therapeutics, Inc. (ORKA) Earnings Summary
ORKA Earnings Beat Rate & Surprise History
Oruka Therapeutics, Inc. (ORKA) has beaten EPS estimates in 2 of its last 8 reported quarters (+25%).
On balance, analysts have tended to overestimate ORKA's earnings. It is currently on a 2-quarter EPS miss streak. The stock has averaged +11.2% the trading day after an EPS beat (positive 50% of the time) and +0.8% after a miss. The average EPS surprise runs -64.4%, with the biggest beat at +12.8% and the biggest miss at -444.9%.
How often ORKA has cleared Wall Street's bar, for EPS and revenue separately, companies can beat one and miss the other. See how analysts are rating it now →
Based on 9 quarters where a report date lines up with price history on record. Reaction day is determined from report timing, for after-market-close (AMC) reports, the reaction shows up the next trading day; for before-market-open (BMO) reports, it's the report day itself.
| Result | Next day | 5 trading days | 20 trading days |
|---|---|---|---|
| EPS beat | +11.2% (50% pos, n=2) | +18.4% (100% pos, n=2) | +60.6% (100% pos, n=2) |
| EPS miss | +0.8% (67% pos, n=6) | +0.6% (50% pos, n=6) | +0.3% (60% pos, n=5) |
Average earnings-day move (either direction): +7.1%. Largest on record: +25.0%.
Every quarter with reaction data, side by side. Rows where the surprise direction and the stock's move disagree are highlighted.
| Quarter | Report Date | EPS Surprise | Rev Surprise | Next-Day Move |
|---|---|---|---|---|
| Q2 '26 | Aug 10, 2026 | -14.7% | — | +6.4% |
| Q1 '26 | May 13, 2026 | -2.6% | — | +1.1% |
| Q4 '25 | Mar 12, 2026 | +12.8% | — | +25.0% |
| Q3 '25 | Nov 12, 2025 | -17.4% | — | -6.8% |
| Q2 '25 | Aug 11, 2025 | -9.7% | — | +6.9% |
| Q1 '25 | May 14, 2025 | +1.8% | — | -2.6% |
| Q4 '24 | Mar 6, 2025 | -40.6% | — | +3.9% |
| Q3 '24 | Nov 13, 2024 | -444.9% | — | -6.4% |
| Q2 '24 | Aug 1, 2024 | — | — | +5.1% |
Beat/miss alone doesn't say how big, a company that beats by 0.1% every quarter behaves very differently from one that swings ±20%.
| Avg Surprise | Median | Largest Beat | Largest Miss | |
|---|---|---|---|---|
| EPS | -64.4% | -12.2% | +12.8% | -444.9% |
More analysts covering a stock generally means more scrutiny and (often) tighter estimates.
Average surprise size by fiscal quarter, some businesses are just more predictable in certain quarters than others.
| Fiscal Quarter | Avg EPS Surprise | Avg Revenue Surprise | Years on Record |
|---|---|---|---|
| Q1 | -0.4% | — | 2 |
| Q2 | -12.2% | — | 3 |
| Q3 | -231.2% | — | 2 |
| Q4 | -13.9% | — | 2 |
Each quarter compared to the same fiscal quarter one year earlier, the standard way to strip out seasonality.
| Quarter | Report Date | EPS Growth | Revenue Growth |
|---|---|---|---|
| Q2 '26 | Aug 10, 2026 | -5.2% | — |
| Q1 '26 | May 13, 2026 | -16.0% | — |
| Q4 '25 | Mar 12, 2026 | +15.6% | — |
| Q3 '25 | Nov 12, 2025 | +63.9% | — |
| Q2 '25 | Aug 11, 2025 | +73.9% | — |
Objective, rule-based checks, not a subjective rating.
How often does ORKA beat EPS estimates?
Oruka Therapeutics, Inc. has beaten EPS estimates in 2 of its last 8 reported quarters, a +25% beat rate. The average surprise is -64.4%.
How does ORKA's stock react to earnings?
Over 9 quarters with price data on record, ORKA has averaged +11.2% the trading day after an EPS beat (positive 50% of the time) and +0.8% after a miss (positive 67% of the time).
What is ORKA's biggest earnings surprise?
ORKA's largest EPS beat on record is +12.8%, and its largest EPS miss is -444.9%.
Is ORKA currently on an earnings beat or miss streak?
ORKA is on a 2-quarter EPS miss streak. Its longest beat streak on record is 1 quarters; its longest miss streak is 2 quarters.
Do analysts usually underestimate or overestimate ORKA?
Analysts have tended to overestimate ORKA's results, based on a +25% EPS beat rate over the last 8 reported quarters.
Every reported quarter on record, estimate vs. actual.
| Quarter | Report Date | EPS Est | EPS Actual | EPS Surprise | Revenue Est | Revenue Actual | Revenue Surprise | Analysts |
|---|---|---|---|---|---|---|---|---|
| Q2 '26 | Aug 10, 2026 | -$0.53 | -$0.61 | -14.7% | $0.00 | $0.00 | — | 7 |
| Q1 '26 | May 13, 2026 | -$0.56 | -$0.58 | -2.6% | $0.00 | $0.00 | — | 7 |
| Q4 '25 | Mar 12, 2026 | -$0.62 | -$0.54 | +12.8% | $0.00 | $0.00 | — | 7 |
| Q3 '25 | Nov 12, 2025 | -$0.59 | -$0.69 | -17.4% | $0.00 | $0.00 | — | 6 |
| Q2 '25 | Aug 11, 2025 | -$0.53 | -$0.58 | -9.7% | $0.00 | $0.00 | — | 4 |
| Q1 '25 | May 14, 2025 | -$0.51 | -$0.50 | +1.8% | $0.00 | $0.00 | — | 3 |
| Q4 '24 | Mar 6, 2025 | -$0.46 | -$0.64 | -40.6% | $0.00 | $0.00 | — | 3 |
| Q3 '24 | Nov 13, 2024 | -$0.35 | -$1.91 | -444.9% | $0.00 | $0.00 | — | 3 |
| Q2 '24 | Aug 1, 2024 | — | -$2.22 | — | — | $0.00 | — | — |